Evaluation of therapeutic candidates based on a number of psychedelic compounds, such as ketamine and psilocybin, <Roots Analysis> Knowpia

Psychedelic substances have been demonstrated to interact with a variety of neurotransmitter pathways, including those involving serotonin, acetylcholine, norepinephrine, and dopamine. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of psychedelic substances. Further, experts believe that psychedelics, at appropriate doses, can be used to address some of the serious psychological implications associated with the COVID-19 pandemic.

To order this 250+ page report, which features 120+ figures and 135+ tables, please visit this - https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html

The over USD 6.5 billion (by 2030) financial opportunity within the psychedelic therapeutics market has been analyzed across the following segments:

§ Target Disease Indication

Anxiety and Depression
Trauma
Pain Disorder
Sleep related Disorder

§ Origin of Psychedelic Substance

Natural
Synthetic

§ Type of Psychedelic Substance

Gamma-hydroxybutyrate
Ketamine
MDMA
Psilocybin

§ Route of Administration

Oral
Intranasal
Sublingual

§ Key Geographies

North America
Europe
Asia-Pacific

The Global Psychedelic Therapeutics Market, 2020-2030” report features the following companies, which we identified to be key players in this domain:

§ Celon Pharma

§ iX Biopharma

§ MAPS Public Benefit

§ MindMed

§ Janssen Pharmaceuticals

§ Jazz Pharmaceutical

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape: Psychedelic Therapeutics

5. Company Profiles

6. Clinical Trial Analysis